As a central goal of PF Awareness Month and their ongoing work, the Pulmonary Fibrosis Foundation aims to improve diagnostic delays and misdiagnoses in this patient population.
Antiplatelet therapy may delay progression of COPD, decrease the risk for acute exacerbations, improve quality of life, and even reduce all-cause mortality.
In the midst of the COVID-19 pandemic, patients with lung cancer face an increased risk of disease progression, reduced survival, and worse quality of life associated with delayed treatment.
Use of prophylactic antimicrobial therapy was not associated with a reduction in mortality or transfer to critical care compared with patients managed with supportive care only.
A new cystic fibrosis transmembrane conductance regulator modulator treatment has been approved by the FDA for use in patients aged 12 years and older.
Adults with cardiac arrest have better outcomes with continuous compressions with asynchronous ventilations or compression-to-ventilation ratios of 30:2.
